Drugs

Andrew Armstrong: Pleased to share our ARCHES analysis of efficacy, safety, and QOL of enza/ADT in men w/mHSPC by age

Photo of Andrew Armstrong taken from goodrx.com

Dec 15, 2023, 06:25

Andrew Armstrong: Pleased to share our ARCHES analysis of efficacy, safety, and QOL of enza/ADT in men w/mHSPC by age

Andrew Armstrong, Professor of Medicine, Surgery, Pharmacology and Cancer Biology at the Duke Cancer Institute, shared on X/Twitter:

“Pleased to share our ARCHES analysis of efficacy, safety, and quality of life of enzalutamide (ENZA)/androgen-deprivation therapy (ADT) in men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) by age (>75 vs <75) in the European Urology Oncology journal.”

For the article, click here.
Source: Andrew Armstrong/X

Andrew Armstrong androgen-deprivation therapy (ADT) ARCHES cancer Duke Cancer Institute enzalutamide (ENZA) European Urology Oncology Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) OncoDaily Oncology

Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 10

OncoThon 2024 Raises $1.3 Million for Pediatric Cancer Research

Richard Sullivan: Do we need a 'new' Geneva Convention and protocols?

Remembering Virgil Abloh: Louis Vuitton’s Creative Director Honored at 41 After His Brave Battle with Cardiac Angiosarcoma

Special Coverage